Fleur is an independent health economist, and has been in the pharmaceutical industry for many years, previously leading global health outcomes teams at GSK across many therapeutic areas. Fleur is a recognized industry expert in Health Technology Assessment.  In the charity sector, drawing on personal experience in rare disease, and working with leading patient organisations Duchenne UK and PPMD in the US, she conceptualized and leads Project HERCULES, a unique collaboration across industry, academia and government bodies generating a gold standard disease level health outcomes evidence base in Duchenne Muscular Dystrophy.